Personalized mRNA Tumor Vaccine

PreclinicalVaccine

Personalized mRNA Tumor Vaccine is one of 39 biologic programs targeting Digestive System Neoplasm. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Digestive System NeoplasmActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Digestive System NeoplasmPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Phase 3

11 2

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

19 3

Navelbine

PPierre Fabre Medicament

Phase 3

24 4

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Digestive System Neoplasm1 trial

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms

Unknown status·—·N/A·NCT03468244·24 enrolled

Non-Small Cell Lung Cancer1 trial

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer

Unknown status·SStemirna Therapeutics·N/A·NCT03908671·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Personalized mRNA Tumor Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Personalized mRNA Tumor Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Personalized mRNA Tumor Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stemirna Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: SStemirna Therapeutics

Personalized mRNA Tumor Vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Digestive System Neoplasm1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News